Astrocyte�derived exosomes contribute to pathologies of NMOSD in rodent model

Yi Xie,Bo Chen,Qiong Wang,Xuejiao Chen,Wenwen Lai,Yaping Xu,Saiyue Deng,Zhiyuan Yu,Minjie Xie,Bitao Bu,Dapeng Mou,Chenju Yi,Fengfei Ding,Wei Wang

DOI: https://doi.org/10.1002/ana.26650

IF: 11.2

2023-03-28

Annals of Neurology

Abstract:Objective Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory demyelinating disease that leads to severe disability. A large proportion of NMOSD patients are seropositive for aquaporin�4 autoantibodies (AQP4�IgG, named as NMO�IgG) targeting the AQP4, which is selectively expressed on astrocytes in central nervous system (CNS). This study tests the hypothesis that in response to NMO�IgG, the pathogenic astrocyte�derived exosomes are released and injure the neighboring cells. Methods IgG purified from serum of either NMOSD patients or healthy controls were used to generate astrocyte�derived exosomes (AST�ExosNMO versus AST�ExosCON) in cultured rat astrocytes. The exosomes were respectively delivered to cultured rat oligodendrocytes in vitro, tissue culture of rat optic nerve ex vivo, and rat optic nerve in vivo to evaluate the pathogenic roles of AST�ExosNMO. The miRNA sequencing of AST�Exos and verification were performed to identify the key pathogenic miRNA. The custom�designed AAV antagonizing the key miRNA was evaluated for its therapeutic effects in vivo. Moreover, the serum levels of the key exosomal miRNA were measured between NMOSD patients and healthy controls. Results AST�ExosNMO led to notable demyelination both in cultured oligodendrocytes and optic nerve tissue. Exosomal miR�129�2�3p was identified as the key miRNA mediating the demyelinating pathogenesis via downstream target gene SMAD3. AAV antagonizing miR�129�2�3p protected against demyelination in NMOSD rodent model. The serum exosomal miR�129�2�3p level was significantly elevated in NMOSD patients and correlated with disease severity. Interpretation Astrocytes targeted by NMO�IgG release pathogenic exosomes that could potentially be used as therapeutic targets, or disease monitoring biomarkers in NMOSD. This article is protected by copyright. All rights reserved.

neurosciences,clinical neurology